The efficacy and safety of vitamin D supplementation for the treatment of NAFLD/NASH

The efficacy and safety of vitamin D supplementation for the treatment of NAFLD/NASH - The efficacy and safety of vitamin D supplementation for the treatment of NAFLD/NASH

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017150

Enrollment

Registered

2015-04-17

Start date

2015-04-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD/NASH

Interventions

Patients were treated with vitamin D supplementation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Taking alcohol less than 20g/day 2.NAFLD/NASH was diagnosed by liver biopsy

Exclusion criteria

Exclusion criteria: 1.pregnant woman or lactating mother 2.poorly controlled heart failure 3.poorly controlled diabetes or hypertension 4.evere renal disorder 5.decompensated liver cirrhosis 6.other liver diseases, including autoimmune hepatitis, primary biliary cirrhosis and alcoholic hepatitis, liver failure 7.positive result for hepatitis C antibody, hepatitis B surface antigen and antibody to human immunodeficiency virus type-1 8.hypercarcemia 9.hyperparathyroidism 10.medication with other vitamin preparations 11.Judged by investigator not to be appropriate for inclusion in this study

Design outcomes

Primary

Measure	Time frame
The liver function and the degree of liver fibrosis after vitamin D supplementation for 48weeks	—

Secondary

Measure	Time frame
1.The lipid and glycometabolism after vitamin D supplementation for 48weeks 2.The safety of vitamin D supplementation	—

Countries

Japan

Contacts

Public ContactMasanori Atsukawa

Nippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology

atsukawa-nms@umin.ac.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026